Top

Breast Cancer Research and Treatment

Published in:

01-10-2018 | Clinical trial

CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy

Authors: Laura E. Jansen, Wendy A. Teft, Rhiannon V. Rose, Daniel J. Lizotte, Richard B. Kim

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Abstract

Purpose

Tamoxifen is frequently prescribed to prevent breast cancer recurrence. Tamoxifen is a prodrug and requires bioactivation by CYP2D6. Tamoxifen use is often limited by adverse effects including severe hot flashes. There is paucity of prospectively collected data in terms of CYP2D6 genotype and measured tamoxifen, 4-hydroxytamoxifen and endoxifen concentrations in relation to hot flash severity during tamoxifen therapy.

Methods

We conducted a longitudinal prospective study of breast cancer patients on tamoxifen (n = 410). At each visit, blood samples were collected, and patients completed a standardized hot flash survey (n = 1144) that reflected hot flash severity during the 7 days prior to the visit. Plasma concentrations of tamoxifen, 4-hydroxytamoxifen, and endoxifen were measured using liquid chromatography-tandem mass spectrometry and genotyping was carried out for CYP2D6. A linear mixed-effects regression analysis assessed the association of covariates in relation to the hot flash severity score (HFSS).

Results

Median age at first assessment was 50 years with 61.9% of patients considered peri-menopausal. Most patients (92.2%) experienced hot flash symptoms with 51.0% having low HFSS (0–4) and 7.32% experiencing HFSS > 25. Age was significantly associated with hot flash severity, with patients aged 45–59 more likely to have higher HFSS. Neither duration of tamoxifen therapy nor observed tamoxifen, endoxifen and 4-hydroxy tamoxifen plasma concentration predicted hot flash severity. Genetic variation in CYP2D6 or CYP3A4 was not predictive of hot flash severity.

Conclusions

Hot flash severity during tamoxifen therapy can not be accounted for by CYP2D6 genotype or observed plasma concentration of tamoxifen, 4-hydroxytamoxifen, or endoxifen.

Ahern TP, Hertz DL, Damkier P et al (2017) Cytochrome P-450 2D6 (CYP2D6) Genotype and breast cancer recurrence in tamoxifen-treated patients: evaluating the importance of loss of heterozygosity. Am J Epidemiol 185:75–85CrossRefPubMedPubMedCentral

Hawse JR, Subramaniam M, Cicek M et al (2013) Endoxifen’s molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens. PLoS ONE 8:e54613CrossRefPubMedPubMedCentral

Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471–478CrossRefPubMed

Murdter TE, Schroth W, Bacchus-Gerybadze L et al (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708–717CrossRefPubMed

Baxter SD, Teft WA, Choi YH, Winquist E, Kim RB (2014) Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22. Breast Cancer Res Treat 145:419–428CrossRefPubMed

Zembutsu H (2015) Pharmacogenomics toward personalized tamoxifen therapy for breast cancer. Pharmacogenomics 16:287–296CrossRefPubMed

Sideras K, Ingle JN, Ames MM et al (2010) Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 28:2768–2776CrossRefPubMedPubMedCentral

Binkhorst L, Mathijssen RH, van Herk-Sukel MP et al (2013) Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer ResTreat 139:923–929CrossRef

Kelly CM, Juurlink DN, Gomes T et al (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693CrossRefPubMedPubMedCentral

10.

Madlensky L, Natarajan L, Tchu S et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89:718–725CrossRefPubMedPubMedCentral

11.

Saladores P, Murdter T, Eccles D et al (2015) Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J 15:84–94CrossRefPubMed

12.

Bhave MA, Henry NL (2017) Extended endocrine therapy: is 5 years enough? Curr Oncol Rep 19:16CrossRefPubMed

13.

Rossmanith WG, Ruebberdt W (2009) What causes hot flushes? The neuroendocrine origin of vasomotor symptoms in the menopause. Gynecol Endocrinol 25:303–314CrossRefPubMed

14.

Del RM, Citi V, Crucitta S et al (2016) Pharmacogenetics of CYP2D6 and tamoxifen therapy: light at the end of the tunnel? Pharmacol Res 107:398–406CrossRef

15.

Deecher DC, Dorries K (2007) Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health 10:247–257CrossRefPubMed

16.

Kronenberg F (2010) Menopausal hot flashes: a review of physiology and biosociocultural perspective on methods of assessment. J Nutr 140:1380S–1385SCrossRefPubMed

17.

Lorizio W, Wu AH, Beattie MS et al (2012) Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer ResTreat 132:1107–1118CrossRef

18.

Mortimer JE, Flatt SW, Parker BA et al (2008) Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 108:421–426CrossRefPubMed

19.

Goetz MP, Rae JM, Suman VJ et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312–9318CrossRefPubMed

20.

Henry NL, Rae JM, Li L et al (2009) Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer ResTreat 117:571–575CrossRef

21.

Sestak I, Kealy R, Nikoloff M et al (2012) Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. Br J Cancer 107:230–233CrossRefPubMedPubMedCentral

22.

Dezentje VO, Gelderblom H, van Schaik RH et al (2014) CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast Cancer Res Treat 143:171–179CrossRefPubMed

23.

Fox P, Balleine RL, Lee C et al (2016) Dose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring-the TADE study. Clin Cancer Res 22:3164–3171CrossRefPubMed

24.

Jager NG, Koornstra RH, Vincent AD et al (2013) Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. BMC Cancer 13:612CrossRefPubMedPubMedCentral

25.

Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H (2001) Methodologic lessons learned from hot flash studies. J Clin Oncol 19:4280–4290CrossRefPubMed

26.

R Core Team (2016) R. A language and environment for statistical computing, in R Foundation for Statistical Computing. Vienna, Austria. (online source)

27.

Gupta P, Sturdee DW, Palin SL et al (2006) Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 9:49–58CrossRefPubMed

28.

Irvin WJ Jr, Walko CM, Weck KE et al (2011) Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 29:3232–3239CrossRefPubMedPubMedCentral

29.

Mortimer J, Behrendt CE (2013) Severe menopausal symptoms are widespread among survivors of breast cancer treatment regardless of time since diagnosis. J Palliat Med 16:1130–1134CrossRefPubMed

Title: CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy
Authors: Laura E. Jansen
Wendy A. Teft
Rhiannon V. Rose
Daniel J. Lizotte
Richard B. Kim
Publication date: 01-10-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4876-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis

Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype

Dosimetric study to assess the feasibility of intraoperative radiotherapy with electrons (ELIOT) as partial breast irradiation for patients with cardiac implantable electronic device (CIED)

Protein N-glycosylation alteration and glycolysis inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells

Screening mammography: benefit of double reading by breast density

The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer